Top in endocrinology: FDA hold on cell therapy trial; endocrine-disrupting chemicals
The FDA recently halted a clinical trial evaluating an investigational stem cell-derived therapy for people with type 1 diabetes with impaired hypoglycemia awareness and severe hypoglycemia.
The clinical hold on VX-880 (Vertex Pharmaceuticals) was due to insufficient data to support dose escalation, according to an industry press release. It was the top story in endocrinology last week.
Another top story covered study data that showed adolescent boys who are exposed to higher levels of two types of endocrine-disrupting chemicals, per- and polyfluoroalkyl substances and phthalates, may have lower areal bone mineral density.
Read these and more top stories in endocrinology below:
FDA places hold on trial of novel cell therapy for type 1 diabetes
The FDA has halted a clinical trial for an investigational stem cell-derived therapy for people with type 1 diabetes, according to an industry press release. Read more.
Endocrine-disrupting chemicals may lower bone mineral density in adolescent boys
Adolescent boys exposed to higher levels of two types of endocrine-disrupting chemicals may have lower areal bone mineral density, according to study data published in The Journal of Clinical Endocrinology & Metabolism. Read more.
Semaglutide use adds CVD-free life-years for high-risk adults with type 2 diabetes
Adults with type 2 diabetes at high risk for cardiovascular disease add 1.7 life-years free of CVD when prescribed semaglutide along with standard diabetes care, according to study findings published in Diabetes Care. Read more.
Look AHEAD: Weight loss of 10% with lifestyle intervention lowers mortality risk
Intensive lifestyle intervention participants in the Look AHEAD randomized controlled trial who lost at least 10% of their body weight had a lower mortality risk compared with those in the control group, according to study data. Read more.
Extended-wear insulin infusion set lasts 7 days for most wearers, with few adverse events
A novel extended-wear insulin infusion set was usable for up to 7 days for most adults with type 1 diabetes, with no change in glycemic control and few adverse events, according to findings published in Diabetes Technology & Therapeutics. Read more.